Studies have displayed that MT1X may serve as a candidate of prognostic indicator and inhibits the progression and metastasis of hepatocellular carcinoma.11 Therefore, we utilized the UALCAN portal to perform the expression of MT1X in AML clinical subtypes classified as FAB in TCGA-LAML dataset, and found that the expression of MT1X was elevated in all subtypes of AML and was the highest in M5. Here, MT1X is linked to hepatocellular carcinoma.